2
|
Flanagan ME, Abramite JA, Anderson DP, Aulabaugh A, Dahal UP, Gilbert AM, Li C, Montgomery J, Oppenheimer SR, Ryder T, Schuff BP, Uccello DP, Walker GS, Wu Y, Brown MF, Chen JM, Hayward MM, Noe MC, Obach RS, Philippe L, Shanmugasundaram V, Shapiro MJ, Starr J, Stroh J, Che Y. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J Med Chem 2014; 57:10072-9. [PMID: 25375838 DOI: 10.1021/jm501412a] [Citation(s) in RCA: 213] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymatic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein. However, covalent approaches carry additional risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets. Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biologically relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles. We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.
Collapse
Affiliation(s)
- Mark E Flanagan
- Center of Chemistry Innovation and Excellence, and ‡Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc. , Eastern Point Road, Groton, Connecticut 06340, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Magee TV, Brown MF, Starr JT, Ackley DC, Abramite JA, Aubrecht J, Butler A, Crandon JL, Dib-Hajj F, Flanagan ME, Granskog K, Hardink JR, Huband MD, Irvine R, Kuhn M, Leach KL, Li B, Lin J, Luke DR, MacVane SH, Miller AA, McCurdy S, McKim JM, Nicolau DP, Nguyen TT, Noe MC, O’Donnell JP, Seibel SB, Shen Y, Stepan AF, Tomaras AP, Wilga PC, Zhang L, Xu J, Chen JM. Discovery of Dap-3 Polymyxin Analogues for the Treatment of Multidrug-Resistant Gram-Negative Nosocomial Infections. J Med Chem 2013; 56:5079-93. [DOI: 10.1021/jm400416u] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Thomas V. Magee
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Matthew F. Brown
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jeremy T. Starr
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - David C. Ackley
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Joseph A. Abramite
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jiri Aubrecht
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Andrew Butler
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jared L. Crandon
- Center
for Anti-Infective Research
and Development, Hartford Hospital, Hartford,
Connecticut 06102, United States
| | - Fadia Dib-Hajj
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Mark E. Flanagan
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Karl Granskog
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Joel R. Hardink
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Michael D. Huband
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Rebecca Irvine
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Michael Kuhn
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Karen L. Leach
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Bryan Li
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Jian Lin
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - David R. Luke
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Shawn H. MacVane
- Center
for Anti-Infective Research
and Development, Hartford Hospital, Hartford,
Connecticut 06102, United States
| | - Alita A. Miller
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Sandra McCurdy
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | | | - David P. Nicolau
- Center
for Anti-Infective Research
and Development, Hartford Hospital, Hartford,
Connecticut 06102, United States
| | - Thuy-Trinh Nguyen
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Mark C. Noe
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - John P. O’Donnell
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Scott B. Seibel
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Yue Shen
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Antonia F. Stepan
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Andrew P. Tomaras
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| | - Paul C. Wilga
- CeeTox, Inc., Kalamazoo, Michigan 49008,
United States
| | - Li Zhang
- WuXi AppTech Co., Ltd., Shanghai, P.R. China
| | | | - Jinshan Michael Chen
- Pfizer Worldwide Research & Development, Pfizer, Inc., Groton, Connecticut 06340, United States
| |
Collapse
|
5
|
Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, Collantes EM, Desbonnet C, Doroski M, Doty J, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, McAllister L, McElroy E, Menard CA, Mitton-Fry M, Mullins L, Noe MC, O'Donnell J, Oliver R, Penzien J, Plummer M, Shanmugasundaram V, Thoma C, Tomaras AP, Uccello DP, Vaz A, Wishka DG. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J Med Chem 2012; 55:1662-70. [PMID: 22257165 DOI: 10.1021/jm2014875] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.
Collapse
Affiliation(s)
- Justin I Montgomery
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG. Potent inhibitors of LpxC for the treatment of Gram-negative infections. J Med Chem 2012; 55:914-23. [PMID: 22175825 DOI: 10.1021/jm2014748] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid.
Collapse
Affiliation(s)
- Matthew F Brown
- Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Hwang HJ, Carey JR, Brower ET, Gengenbach AJ, Abramite JA, Lu Y. Blue Ferrocenium Azurin: An Organometalloprotein with Tunable Redox Properties. J Am Chem Soc 2005; 127:15356-7. [PMID: 16262384 DOI: 10.1021/ja054983h] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A ferrocene derivative (2-[(methylsulfonyl)thio]ethylferrocene) (1) has been synthesized and incorporated into apo-azurin from Pseudomonas aeruginosa by covalent attachment to the highly conserved Cys112. The resulting artificial organometalloprotein (a protein containing organometallic compounds in the active site) has been characterized by UV-vis, electrospray mass spectrometry, and cyclic voltammetry (CV). Incorporation of 1 into azurin resulted in a higher solubility of the ferrocene group and improved stability of the ferrocenium species in aqueous solution, as shown by a more intense UV-vis absorption and a more reversible CV of the attached ferrocene group, respectively. The incorporation of 1 also increased the reduction potential of the complex from 402 to 579 mV (vs NHE), consistent with the ferrocene group being encapsulated inside the hydrophobic environment of the protein. Modulation of the reduction potential of ferrocene by residues near the secondary coordination sphere has also been demonstrated. Raising the pH from 4 to 9 resulted in a greater than 80 mV decrease in reduction potential of the protein-bound ferrocene (from 579 to 495 mV), while replacing Met121, an amino acid residue in close proximity to the ferrocene group with a positively charged Arg or negatively charged Glu, resulted in the predicted increase or decrease in reduction potential at all pH values. Similarly, substitution of Met121 with a more hydrophobic Leu raised the reduction potential. The increased solubility, stability, and tune-ability of this organometalloprotein make it an ideal choice for carrying out a number of biological reactions, such as long-range electron transfer or sensing. As an example of such applications, stoichiometric oxidation of ferrocytochrome c by the blue ferrocenium azurin was demonstrated.
Collapse
Affiliation(s)
- Hee Jung Hwang
- Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
| | | | | | | | | | | |
Collapse
|